English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol (Symbicor ® Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol (Seretide ® ) plus as-needed, short-acting β 2 agonists (SABAs) in Taiwanese patients with inadequate asthma control.

drug design development and therapy

&lt;p&gt;Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β&lt;sub&gt;2&lt;/sub&gt; Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study&lt;/p&gt;